ライフサイエンスコーパス: deoxythymidine

1 stable triplexes than did TFOs containing 2'-deoxythymidine.

2 phthylethylcarboxyamide)-2'-deoxyuridine for deoxythymidine.

3 reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine.

4 in the presence of drugs [e.g., 3'-azido-3'-deoxythymidine, (-)2/,3'-dideoxy-3'-thiacytidine, hydrox

5 ine; 2'3'-dideoxyinosine; 2', 3'-didehydro-3'deoxythymidine; 2',3'-dideoxy-3'-thiacytidine; and 4-[2-

6 When 2'-deoxythymidine-3',5'-cyclic diphosphate, or the cyclic p

7 ated using thymidine 5'-triphosphate (dTTP), deoxythymidine 5'-(beta, gamma-methylenetriphosphate)(dT

8 se beta-DNA template-primer-chromium(III).2'-deoxythymidine 5'-beta,gamma-methylenetriphosphate [Cr(I

9 ases show identical binding to a 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP)-terminated prime

10 plication fidelity, particularly for thymine-deoxythymidine 5'-monophosphate (T-dTMP) but not adenine

11 wild type TS but is converted to 3-methyl 2'-deoxythymidine 5'-monophosphate by many TS Asn 229 mutan

12 '-deoxyuridine 5'-monophosphate (dUMP) to 2'-deoxythymidine 5'-monophosphate.

13 o describe aqueous ionization energies of 2'-deoxythymidine 5'-phosphate (5'-dTMP-) and 2'-deoxycytid

14 generation of DNA precursors in the form of deoxythymidine 5'-phosphate is particularly important fo

15 idine 5'-triphosphate (dTTP) and 3'-azido-3'-deoxythymidine 5'-triphosphate (AZTTP) by wild-type HIV-

16 examine the binding and incorporation of 2'-deoxythymidine 5'-triphosphate (dTTP) and 3'-azido-3'-de

17 ribonucleotide in the syn conformation and a deoxythymidine 5'-triphosphate (dTTP), and that the fit

18 hod is presented for the determination of 2'-deoxythymidine 5'-triphosphate and 2'-deoxycytidine 5'-t

19 ucleoside triphosphates, such as 3'-azido-3'-deoxythymidine 5'-triphosphate and 3'-deoxythymidine 5'-

20 ido-3'-deoxythymidine 5'-triphosphate and 3'-deoxythymidine 5'-triphosphate, can also penetrate the v

21 c pathway, deoxycytidine 5'-triphosphate and deoxythymidine 5'-triphosphate, which act as an activato

22 The increase in deoxythymidine 5'-triphosphate-G mispairs was confirmed

23 sed to define the distribution of 5-bromo-2'-deoxythymidine (5-BrdT) modified antisense oligonucleoti

24 n-Crick-like pairing between O(6)-MeG and 2"-deoxythymidine-5"-[(alpha, beta)-imido]triphosphate (app

25 orporated dA or dT opposite 1,N(6)-dA and 2'-deoxythymidine-5'-[(alpha,beta)-imido]triphosphate oppos

26 , which increases the excision of 3-azido-3'-deoxythymidine-5'-monophosphate (AZTMP) in vitro and inc

27 ate synthase reaction within the crystal, 2'-deoxythymidine-5'-monophosphate and 7,8-dihydrofolate, s

28 of the intermediate to form the product, 2'-deoxythymidine-5'-monophosphate.

29 rate (and/or not excise) the dTTP analog, 2'-deoxythymidine-5'-O-(alpha-phosphonomethyl)-beta, gamma-

30 thesize 5'-P(alpha)-boranodiphosphates of 2'-deoxythymidine, adenosine, guanosine, and uridine.

31 ral effect of stavudine (2', 3'-didehydro-3'-deoxythymidine) against human immunodeficiency virus (HI

32 ts, the thymidine analogs 3'-(18)F-fluoro-3'-deoxythymidine and (18)F-1-(2'-deoxy-2'-fluoro-beta-d-ar

33 he anti-HIV nucleoside analogues 3'-azido-3'-deoxythymidine and 2',3'-didehydro-2', 3'-dideoxythymidi

34 nferred high-level resistance to 3'-azido-3'-deoxythymidine and 2,3-didehydro-2,3-dideoxythymidine by

35 Beta-D-2',3'-Didehydro-3'-deoxythymidine and beta-D-2'-ara-fluoro-2',3'-dideoxyade

36 It is capable of phosphorylating deoxythymidine and deoxyuridine as does human thymidine

37 sly described for dCTP, protonation of N3 in deoxythymidine and not deoxycytidine would facilitate hy

38 A with a ribouridine in lieu of the critical deoxythymidine and show that this substitution results i

39 No reactivity was observed between deoxythymidine and the sugars.

40 s of two NRTIs, zidovudine [AZT (3'-azido-3'-deoxythymidine)] and didanosine [ddI (2',3'-dideoxyinosi

41 alues for adenosine, guanosine dihydrate, 2'-deoxythymidine, and cytidine are measured on natural abu

42 Deoxyguanosine, deoxyadenosine, deoxythymidine, and deoxycytidine were used as the model

43 ubstrates containing 3'-deoxyadenosine or 3'-deoxythymidine at specific sites and acceptor oligonucle

44 s was stalled by the presence of 3'-azido-3'-deoxythymidine at the primer terminus, possibly contribu

45 served in HBV-infected patients, 3' azido-3'-deoxythymidine (AZT [zidovudine]) had no effect on WHV r

46 Photoaffinity labeling with the 3'-azido-3'-deoxythymidine (AZT) analog 3',5-diazido-2', 3'-dideoxyu

47 3'-Azido-3'-deoxythymidine (AZT) and 3'-deoxythymidine (ddT) were ch

48 reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine (AZT) and by mutation of the integrase ge

49 by augmented phosphorylation of 3'-azido-3'-deoxythymidine (AZT) and concomitantly greater sensitivi

50 also phenotypically resistant to 3'-azido-3'-deoxythymidine (AZT) and to the combination of 3TC and A

51 ur laboratory have characterized 3'-azido-3'-deoxythymidine (AZT) as a potent inhibitor of glycosphin

52 of phosphoramidate monoesters of 3'-azido-3'-deoxythymidine (AZT) bearing aliphatic amino acid methyl

53 hat antiretroviral drugs such as 3'-azido-3'-deoxythymidine (AZT) can influence the in vivo mutation

54 n domain increased resistance to 3'-azido-3'-deoxythymidine (AZT) from 11-fold to as much as 536-fold

55 fied as conferring resistance to 3'-azido-3'-deoxythymidine (AZT) in Escherichia coli.

56 and to test our hypothesis that 3'-azido-3'-deoxythymidine (AZT) increases the retroviral mutation r

57 e analogues ganciclovir (GCV) and 3'-azido-3'deoxythymidine (AZT) into their active, cytotoxic forms.

58 The resistance of HIV-1 to 3'-azido-3'-deoxythymidine (AZT) involves phosphorolytic excision of

59 ency virus (HIV) 1 resistance to 3'-azido-3'-deoxythymidine (AZT) involves reverse transcriptase (RT)

60 vity of the structurally similar 3'-azido-3'-deoxythymidine (AZT) phosphoramidates 1-6 and 3'-fluoro-

61 sure of combination therapy with 3'-azido-3'-deoxythymidine (AZT) plus 2',3'-dideoxyinosine.

62 transcriptase (RT) give rise to 3'-azido-3'-deoxythymidine (AZT) resistance by a mechanism that has

63 erse transcriptase (RT) increase 3'-azido-3'-deoxythymidine (AZT) resistance in the context of thymid

64 on domain significantly increase 3'-azido-3'-deoxythymidine (AZT) resistance up to 536 times over wil

65 reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine (AZT) suggest that reverse transcription

66 ncy virus type 1 is resistant to 3'-azido-3'-deoxythymidine (AZT) when four amino acid substitutions

67 HIV-2, resistance to zidovudine (3'-azido-3'-deoxythymidine (AZT)) and other NRTIs is conferred by mu

68 Previous studies have shown that 3'-azido-3'-deoxythymidine (AZT), (-)2',3'-dideoxy-3'-thiacytidine (

69 Another telomerase inhibitor, 3'-azido-3'-deoxythymidine (AZT), at a concentration that produced l

70 ctivity was more pronounced with 3'-azido-3'-deoxythymidine (AZT), in which 78% of the reaction produ

71 We sought to determine if 3'-azido-3'-deoxythymidine (AZT), the primary treatment for human im

72 in deciphering the mechanisms of 3'-azido-3'-deoxythymidine (AZT)-resistance by human immunodeficienc

73 an in vivo selection to identify 3'-azido-3'-deoxythymidine (AZT)-resistant mutants of rat DNA polyme

74 transcriptase (RT), such as the 3'-azido-3'-deoxythymidine (AZT)-resistant variant AZT-R (M41L/D67N/

75 A high-level 3'-azido-3'-deoxythymidine (AZT)-resistant variant containing delta

76 ction in p24 antigen produced by 3'-azido-3'-deoxythymidine (AZT)-sensitive HIV-1 isolates, A012 and

77 ral used to treat HIV infection, 3'-azido-3'-deoxythymidine (AZT).

78 FIV mutant that is resistant to 3'-azido-3'-deoxythymidine (AZT).

79 tase sensitivity to the inhibitor 3'-azido-3'deoxythymidine (AZT).

80 terminating nucleoside inhibitor 3'-azido-3'-deoxythymidine (AZT).

81 luoro-3'-thiacytidine (FTC), and 3'-azido-3'-deoxythymidine (AZT).

82 vity of the virus to zidovudine (3'-azido-3'-deoxythymidine; AZT).

83 rs for a hairpin that has six deoxyadenosine-deoxythymidine base pairs.

84 n clinical trials: beta-D-2',3'-didehydro-3'-deoxythymidine, beta-D-2'-ara-fluoro-2', 3'-dideoxyadeno

85 ation of the selective SND1 inhibitor 3', 5'-deoxythymidine bisphosphate (pdTp), inhibited tumor form

86 h unprotected nucleosides (e.g., 3'-azido-3'-deoxythymidine, cytidine, thymidine, uridine, inosine, o

87 cy virus (anti-HIV) agent 2',3'-didehydro-3'-deoxythymidine (D4T), like other 2',3'-dideoxynucleoside

88 ards the anti-HIV prodrug 2',3'-didehydro-3'-deoxythymidine (d4T).

89 The most potent was the 5'-phosphonate of 3'-deoxythymidine (ddT) (apparent Ki value of 63 nM).

90 3'-Azido-3'-deoxythymidine (AZT) and 3'-deoxythymidine (ddT) were chosen as models.

91 terization of an orthogonal NA kinase for 3'-deoxythymidine (ddT), using a new FACS-based screening p

92 ism of the deoxynucleoside monophosphates to deoxythymidine (dT) and deoxycytidine (dC), we hypothesi

93 lowing sequence: d(GCGACTTTTTGNCGC) [N = dU, deoxythymidine (dT) or 5-(3-aminopropyl)-2'-deoxyuridine

94 in complex with DNA containing a template 2'-deoxythymidine (dT) paired with an incoming dNTP or modi

95 ine (rA), cytidine (rC), guanosine (rG), and deoxythymidine (dT), and the nucleoside triphosphates AT

96 ation was used to provide separate peaks for deoxythymidine (dT), deoxyadenosine (dA), and deoxyguano

97 transfer of the gamma-phosphate of ATP to 2'-deoxythymidine (dThd) forming thymidine monophosphate (d

98 o increased circulating levels of thymidine (deoxythymidine, dThd) and deoxyuridine (dUrd) and has be

99 A probe consisting of a pair of deoxythymidines flanked by several 2'-O-methyl-modified

100 mer oligonucleotide probe based on a pair of deoxythymidines flanked by several modified nucleotides

101 Two novel thymidine analogs, 3'-fluoro-3'-deoxythymidine (FLT) and 2',3'-didehydro-3'-deoxy-4'-eth

102 (AZT) phosphoramidates 1-6 and 3'-fluoro-3'-deoxythymidine (FLT) phosphoramidates 7-10 are reported.

103 3'-Fluoro-3'-deoxythymidine (FLT) was identified as one of the most p

104 Indeed, we find that TDG flipping of deoxythymidine from a G.T mispair is robustly monitored

105 cking proofreading activity, Kf (exo-), than deoxythymidine glycol triphosphate (dTgTP).

106 chniques to investigate the incorporation of deoxythymidine --> deoxyuridine (dT --> dU) substitution

107 ecamer d(CGCGAASSCGCG), where S = 4'-thio-2'-deoxythymidine, has converged at R=0.201 for 2605 reflec

108 e show through binding studies that a single deoxythymidine in a telomeric repeat dictates the DNA ve

109 ubated in aqueous solution with 5'-amino- 5'-deoxythymidine in the presence of N-(3-dimethylaminoprop

110 Inclusion of 3'-deoxythymidine in the scissile strand at position -1 per

111 rminus, possibly contributing to 3'-azido-3'-deoxythymidine inhibition.

112 When uridine and 2'-deoxythymidine ionization energies are evaluated, the re

113 nucleotides (ODNs) terminated by 5'-amino-5'-deoxythymidine is described.

114 me class (deoxycytidine, deoxyguanosine, and deoxythymidine kinases, as well as the multisubstrate dN

115 itro, HIV-1 mutants resistant to 3'-azido-3'-deoxythymidine (M41L/D67N/K70R/T215Y/K219Q) and (-)beta-

116 mechanism of synergy, beta-D-(+)-3'-azido-3'-deoxythymidine monophosphate (AZTMP) removal was examine

117 The deoxythymidine monophosphate (dTMP) substrate binding po

118 ucts, deoxycytidine monophosphate (dCMP) and deoxythymidine monophosphate (dTMP), prolongs the life s

119 is of both S-adenosylmethionine (AdoMet) and deoxythymidine monophosphate (dTMP), which are required

120 me responsible for the de novo production of deoxythymidine monophosphate and hence is crucial for DN

121 te synthase ThyX produces the DNA nucleotide deoxythymidine monophosphate from dUMP, using methylenet

122 ed Toxoplasma access to folates required for deoxythymidine monophosphate synthesis, thereby restrict

123 he final step in the de novo biosynthesis of deoxythymidine monophosphate, dTMP, required for DNA rep

124 alyses the de novo pathway for production of deoxythymidine monophosphate.

125 extended our previous study with 3'-azido-3'-deoxythymidine nucleotides and examined the effects on h

126 synthesis were synthesized from 3'-azido-3'-deoxythymidine or 3'-azido-2',3'-dideoxyuridine via acid

127 The commonly used 19mer with two deoxythymidine overhangs (19merTT) variant performed sim

128 23 of RB69 DNA polymerase intercalating into deoxythymidine primers.

129 Previously, we demonstrated that deoxythymidine release from degraded siRNAs reversed the

130 cceptor ODN extended by a single 5'-amino-5'-deoxythymidine residue at its 5'terminus.

131 GGTTGAC-3', where T* denotes the 5'-amino-5'-deoxythymidine residue.

132 ta67+T69G/L74I) leads to a novel 3'-azido-3'-deoxythymidine resistance motif and compensates for impa

133 AZT (3'-azido-3'-deoxythymidine) resistance involves the enhanced excisio

134 s were probed using nicotine and 3'-azido-3'-deoxythymidine, respectively, and significant decreases

135 were enriched in poly-deoxyadenosine or poly-deoxythymidine sequences.

136 Chain-terminating 2'-3'-didehydro 3'-deoxythymidine [stavudine (D4T)] and 2'-3'-dideoxyinosin

137 the B form by 1.6 kcal/mol as compared with deoxythymidine, suggesting that the intrinsic conformati

138 f these modified nucleosides and 5'-amino-5'-deoxythymidine to the corresponding 5'-N-triphosphates t

139 nosine 5'-triphosphate (DXG-TP), 3'-azido-3'-deoxythymidine-TP, and 3TC-TP by using steady state kine

140 ng step in the pathway of helicase-catalyzed deoxythymidine triphosphatase (dTTPase) reaction is the

141 The nucleoside analogue 3'-azido-3'-deoxythymidine triphosphate (AZT-TP) had no effect, wher

142 of liver deoxyuridine triphosphate (dUTP) to deoxythymidine triphosphate (dTTP) was increased and cor

143 ts them from deletion of otherwise essential deoxythymidine triphosphate (dTTP)-producing pathways an

144 hange-inert nucleotide analogue rhodium(III) deoxythymidine triphosphate (Rh.dTTP) to investigate the

145 etylglucosamine-1-phosphate with uridine and deoxythymidine triphosphate (UTP and dTTP, respectively)

146 cleoside analogues indicated that 3'-azido-3'deoxythymidine triphosphate is much more inhibitory than

147 a fidelity and discrimination of 3'-azido-3'-deoxythymidine triphosphate substrates.

148 to several DNA repair pathways by providing deoxythymidine triphosphate that serve as precursors for

149 ase and deoxyuridine triphosphate instead of deoxythymidine triphosphate to reduce the risk of cross

150 in the hairpin dynamics upon the addition of deoxythymidine triphosphate.

151 ridine in tissues and elevated mitochondrial deoxythymidine triphosphate.

152 des with 5' overhangs of deoxyadenosines and deoxythymidines up to nine bases in length were used.

153 do these phages have unusual substitution of deoxythymidine with deoxyuridine (dU) in their DNA, but

154 the amplified DNA product at positions where deoxythymidine would normally be incorporated at a frequ